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ABSTRACT
Introduction. Arterial hypertension affects 
the heart tissue composition which leads to 
structural remodeling of the myocardium. The 
imbalance between synthesis and degradation of 
type I collagen leading to myocardial fibrosis in a 
form of type I collagen fiber accumulation in the 
interstitial and perivascular myocardium. Collagen 
fiber accumulation reduces relaxation stage, 
diastolic suction, myocardial stiffness and diastolic 
dysfunction which affect systolic dysfunction 
leading to heart failure. Concentration of carboxy-
terminal pro peptide of pro collagen type I (PIP) in 
peripheral blood am a synthesis index of type I 
collagen in HHD. Thus, the measurement of PIP is 
useful to monitor myocardial fibrosis stage in heart 
failure and to determine the therapeutic strategy 
that aims not only to reduce arterial pressure and left 
ventricular mass but also to prevent myocardial 
remodeling.
Aim of the study. The aim of the study was to 
ascertain the difference PIP level in patients with the 
heart failure stage A, B, and C which are caused by 
hypertension. The serum concentration of PIP was 
measured by enzyme immunoassay. This research 
was a cross sectional research designed for 
cardiology policlinic's outpatients at Dr. Sardjito 
General Hospital Yogyakarta from August 2009 
until the calculated sample number is fulfilled. 
Method. One-way ANOVA was used to 
analyze the differences between the three groups of 
heart failure stages after being tested for the 
normality using Kolmogorov-Smirnov normality 
test. If the result did not show a normal value, a non-
parametric test would be undergone using Kruskal-
Wallis test followed by Mann-Whitney U test. The 
differences considered as significant if p < 0.05 with 
a confidence interval of 95%.
Result. The research was performed in 64 
patients heart failure caused by hypertension 
consisted of 22 stages A, 19 stage B and 23 stage C. 
PIP mean levels of the group stage B 819.78 ± 91,03 
ng/ml was higher compared stage A 808.47± 80.8 
ng/ml and PIP mean level stage C 852 ± 55.51 ng/ml 
was higher compared stage B. The PIP mean levels 
did not differ statistically significantly (p=0. 317).
Conclusion. There were no significant 
differences in serum level of PIP on the stage heart 
failure A, B and C.
Keywords: Collagen, fibrosis, hypertension, heart 
failure, carboxy-terminal pro peptide
INTRODUCTION 
Hypertension affects approximately 50 
millions of people in the United States and 1 billion 
of people worldwide. The prevalence of 
hypertension will increase at population age if the 
1effective preventive measures are not implemented . 
The data from the Framingham Heart Study 
mentioned that hypertension contributed as much as 
39% of heart failure cases in men and 59% of cases 
2in women .
One complication of hypertension is the 
development of left ventricular hypertrophy. Left 
ventricular hypertrophy is characterized by a 
concentric and circumferential hypertrophy of the 
myofibrils, increased contractility and thickened 
ventricular wall, decreased end diastolic volume and 
1relaxation disturbance .
Hypertension is the most likely risk factor to 
develop heart failure. Myocardial failure in 
hypertension involves various complex events in 
cellular, molecular level and extracellular matrix 
metabolism change. The excess of collagen in the 
myocardium of hypertensive heart disease (HHD) 
patients is mainly due to the imbalance between 
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increased synthesis and unchanged or degraded type 
31 collagen fibers .
Endomyocardial invasive biopsy is one way 
to assess fibrotic tissues in hypertensive disease but 
this technique is not widely implemented and 
managed. Serological determination of collagen 
derived peptides is used as a fibrillar collagen 
turnover marker in various conditions leading to 
4cardiac fibrosis .
The increased myocardial fibrosis as a result 
of the increased type 1 collagen synthesis and its 
deposit may contribute to the development of heart 
3failure in HHD patients . The hypothesis of this 
study is a relationship between type I carboxy 
terminal pro peptide pro collagen level with stage A, 
B and C heart failure patients caused by 
hypertension. 
METHOD
This study used a cross sectional study, 
comparing the average serum level of type I carboxy 
terminal pro peptide procollagen (PIP) in 3 groups of 
heart failure patients, consisting of hypertension 
group (stage A heart failure), hypertension with left 
ventricular hypertrophy (Stage B heart failure), and 
hypertension with left ventricular hypertrophy and 
heart failure symptoms (stage C heart failure). This 
study began in August 2009 to complete.
The Course of the Study
Research subjects were the outpatients in 
cardiology polyclinic of Dr. Sardjito Yogyakarta 
General Hospital diagnosed to be having heart 
failure based on ACC/AHA criteria and willing to 
follow the course of this study.
The inclusion criteria of this study were 
hypertensive heart failure diagnosed based on 
ACC/AHA criteria, heart failure patients on 
treatment and those who were willing to sign the 
informed consent form. The exclusion criteria were 
acute coronary syndrome, IHD, primary valvular 
heart diseases, permanent arrhythmia, diabetes 
mellitus, severe chronic kidney diseases, 
hyperthyroid, alcoholic liver diseases, metabolic 
bone diseases (osteomalacia, Paget's disease, 
rheumatism, bone metastasis), stroke and 
malignancies.
Research Finding and Discussion
Studied variables were:
1. The independent variable was the type I carboxy 
terminal propeptide procollagen (PIP).
2. Dependent variables were hypertension (stage A 
heart failure), hypertension with left ventricular 
hypertrophy (stage B heart failure), hypertension 
with left ventricular hypertrophy along with the 
symptoms of heart failure (stage C heart failure).
3. Other variables measured were age, sex, body 
stature, body weight, BMI, blood profile, random 
blood glucose test, ALT, AST, BUN, creatinine, 
anti-hypertensive drugs, stage of hypertension, 
duration of hypertension, heart rate, left 
ventricular mass, left ventricular mass index, and 
left ventricular hypertrophy.
Measurement
1. The Auscultatory method of blood pressure 
measurement with Sphygmomanometer, 
subjects should be seated quietly for 5 minutes 
with the arm supported at heart level. Spine 
manometer which pumped up beats disappears 
then increase 30 mm Hg. The stethoscope bell 
was placed in position then lowered slowly (2-3 
mmHg/Sec). Systolic blood pressure is the point 
at which the first sound is the heart (korotkoff 1) 
and diastolic blood pressure is the point before 
the disappearance of sound (korotkoff 5).
2. The BMI was calculated by dividing body 
 5weight (kg) and body height (m2).
3. Left ventricular mass (LVM) measured by using 
a recommended formula by American Society of 
Echocardiography, of which LVM = 0.8 [1.04 x 
{(LVIDd + IVSd + PWd) 3- LVIDd3}] + 0.6 
6-7grams. 
4. Left ventricular Mass Index (LVMI) = 
LVM/BSA. The BSA stands for body surface 
area, and was calculated by using Dubois 
formula: 0.007184 x W0.425 x H0.725 (W is for 
body weight in kg and H is for body height in cm) 
6-7
5. Type I carboxy terminal propeptide procollagen 
(PIP) serum was tested using Enzyme 
immunoassay human Procollagen Type I-C-
peptide (EIA human PICP) Takara bio INC 
method with mg/ml as the applied unit.
23
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Study subjects consisted of 22 (34, 37%) 
patients in stage A heart failure group, 19 (29,68%) 
patients in stage B heart failure group, and 23 
(35,93%) patients in stage C heart failure group. 
Overall, there were 21 (32, 81%) male subjects and 
43 (67, 18%) female subjects.
Hypertension stage    
Pre hypertension n (%) 4(18.8) 3(15.78)  6(26.08)  
Stage 1 n (%) 12(54.54) 11(57.89)  7(30.43)  
Stage II n (%) 6(27.27) 5(26.31)  10(43.47)  
Duration HT 
Years (mean±SD) 
7.6±6.5 7.4±4.1  11.6±8.0  
 Treatment
    ACEI n
 
(%)
 
13(59)
 
12(63.15)
 
18(78.26)
 ARB n
 
(%
 
9(40.9)
 
11(57.89)
 
10(43.47)
 â-blocker
 
n (%)
 
5(22.72)
 
4(21.05)
 
11(47.82)
 CCB n
 
(%)
 
10(45.45)
 
14(73.68)
 
9(39.13)
 Furosemidn
 
(%)
 
4(18.18)
 
6(31.57)
 
16(69.56)
 Spironolactonn
 
(%)
 
0(0)
 
0(0)
 
4(17.39)
 Thiazides n (%) 5(22.72) 7(36.84) 1(4.34)
Echocardiography was used as a parameter 
to measure the magnitude of left ventricular 
hypertrophy. Obtained the power of good inter-
observer agreement in interpretation of the ECG 
with a kappa value of 0.69, echocardiography 
parameters are indicated in table 2.
Table 2. Comparison of three groups of variable echocardiography parameters of heart failure
Kruskal-Wallis followed Mann-Whitney U test, statistically significant p<0.05, *p<0.05vs stage A; 
†p<0.05 vs stage B.
After a post hoc analysis using Mann-
Whitney test was done, we found significant 
differences of IVSD, LVIDd and LVPWd only in 
stage B and C group compared to stage A group. 
Mean LVMI value based on BSA stage A, B, and C 
heart failure group, respectively (stage A 97.17 ± 
11.39 g/m2, stage B 136.44 ±25.40 g/m2 and stage C 
154.35 ± 51.51 g/m2)), significant difference of 
LVMI was found among the three heart failure 
groups with p value of p=0. 000. LVH frequency 
Variables
 
Stage A heart
 
failure
 
n=22 
Stage B heart
 
failure
 
n=19  
Stage C heart
 
failure
 
n=23  
P
 
 
EF % (mean±SD) 68.23±7.38 69.89±5.76  65.30±8.17  0.279
IVSD mm (mean±SD) 10.5±1.2 13.6±3.3*  13.3±1.6*  0.000
LVPWd mm (mean±SD) 10.3±0.9 12.2±1.3*  12.6±1.6*  0.000
LVIDd mm (mean±SD) 43.4±3.9 44,1±4,5  48±5.6*  0.018
LVMI g/m2 (mean±SD) 97.17±11.39 136.44±25.40  154.35±51.51*†  0.000
LVM g (mean±SD) 155.21±26.66 216±44.15*  252±89.12*  0.000LVH n (%) 0(0) 19(100) 23(100) 0.000
found about 100% in stage B and C group of heart 
failure.
The PIP level examinations (table 3) of the 
three heart failure groups in this study showed   
results as the following: 808.47 ± 80.8 ng/ml for 
stage A group, 819.78 ± 91.03 ng/ml for stage B 
group and 852 ± 55.51 ng/ml for the stage C group. 
The mean PIP level of the stage B group was higher 
than stage A group and the mean PIP level of the 
stage C group was higher than stage B group, but 
these differences were not statistically significant 
(p=0. 317).
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Table 3. The difference in mean levels of PIP on the three groups of heart failure
Variable Stage A heart 
failure 
Stage B heart  
failure 
Stage C heart  
failure  
P  
 
PIP ng/ml 808.47±80.8 
 
819.78±91.03  
 
852±55.51  
 
0.317  
 
Statistically significant p < 0.05
DISCUSSIONS
This study was conducted in order to obtain 
the PIP level of the three groups of heart failure 
patients. This study resulted in a higher proportion 
of female subjects compared to male subjects.
The mean age of onset of the heart failure in 
stage A, B, and C group respectively were as follow 
57.68 ± 11.44 years old, 56.89 ± 13.09 years old, and 
62.91 ± 7.59 years old.
The mean BMI for stage A group was 23.04 
± 3.39 kg/m2, 24.17 ± 3.12kg/m2 for stage B group 
and 26,88 ± 3,35 kg/m2 for the stage C group. The 
prevalence of hypertension will increase as the 
increased of BMI, central obesity degree, and 
9fasting blood glucose level .
The mean systolic blood pressure for stage 
A, B, and C group respectively were as follows (145 
± 15.35 mmHg, 143, 1 ± 15.3 mmHg, 148 ± 18.5 
mm Hg), stage I hypertension had its highest 
distribution in stage A heart failure group as many as 
12 patients (54.54%), stage II had its highest 
distribution in stage C heart failure group as many as 
10 patients (43.47%).
Measurement of LVMI based on BSA 
resulted in significant differences among stage A 
mean LVMI (g/m2) of 97.17±11.39, stage B of 
136.44±25.40 and stage C of 154.35±51.51 with p 
value of p= 0.000. A LVH frequency of 100% was 
found in stage B and C heart failure groups. A study 
conducted by Chukwuka et al., 2008 found a 
significant difference of LVPWd, LVM and LVMI 
parameters between normotensive and hypertensive 
10subjects .
This study also found the increasing 
thickness of the interventricular septum during 
diastole, the thickening of the left ventricular 
posterior wall during diastole in stage B and C heart 
failure groups, while the mean internal diameter 
during diastole was still within normal limits in 
stage A and B groups. Accumulation of collagen 
fibers decrease of the level of relaxation, diastolic 
suction and passive stiffness because impaired 
diastolic function further reduces diastolic filling 
and lower transduction Cardio myosit contraction in 
the power of thus affecting the development of 
11myocardial systolic performance .
The mean PIP level found in this study were 
819.78 ± 91.03 ng/ml in stage B group which was 
higher than what was found in stage A group of 
808.47 ± 80.8ng/ml and the mean PIP level in stage 
C group was 852 ± 55.51 ng/ml which was higher 
than stage B group, even though those scores were 
not statistically significant among the three groups 
(p=0. 317).
The results found in this study were in 
accordance with the results of a survey conducted by 
Richard et al, in 2007 which comparing PIP level 
115 hypertensive patients with LVH, 38 
hypertensive patients without LVH and 38 
normotensive patients. The study showed an 
increased PIP level in patients with hypertension 
compared to normotensive patients, and there were 
only slight differences between patients with and 
without LVH. Hypertension with LVH correlated 
with cardiomyocytes hypertrophy and the amount 
of myocardial collagen, myocardial fibrosis could 
cause diastolic dysfunction and heart failure. PIP 
level in the circulation acted as type I collagen 
synthesis index and had some correlation with the 
12amount of myocardial fibrosis .
These study results were also consistent 
with the reports made by Liang et al., In 2004 who 
studied about the PIP level in 61 CHF patients and 
20 control subjects, and the study showed that PIP 
level increased significantly compared to normal 
subjects and increased in parallel upon NYHA 
classifications and also no correlation was found 
with any underlying diseases. PIP serum level 
examinations showed synthesis and metabolism of 
cardiac extracellular collagen matrix during left 
13ventricle reconstruction in CHF .
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A study conducted by Querejeta et al. 
(2000), found PIP serum and collagen volume 
fraction (CVF) concentration to be higher (p<0.001) 
in hypertensive patients compared to normotensive 
subjects. PIP level found in hypertensive patients 
with severe fibrosis was higher (p<0.05) compared 
to hypertensive patients with non-severe fibrosis 
4 (108±6 ìg/L) and normotensive patients. A study 
by Querejeta et al, in 2004 found PIP level was 
higher in patients with heart failure compared to 
hypertensive patients without heart failure (p<0.05), 
there was direct correlations between CVF and 
3peripheral PIP .
The results of this study showed that there 
was no significant difference on PIP level among the 
three heart failure groups (P=0.317), this was caused 
by no treadmill and coronary angiography 
undergone to exclude other heart diseases which 
correlated to fibrotic process, which was ischemic 
heart disease (IHD). In order to exclude IHD, 
researchers only performed electrocardiography 
and echocardiography. In classifying stage B and C 
heart failure, researchers examined whether there 
were any symptoms of heart failure before or prior 
heart failure symptoms are subjective.
Several weaknesses of this study were on 
the research design employed, a cross sectional 
design which had a weakness in determining the 
causal relationship of the diseases. This study did 
not perform treadmill test and coronary 
angiography to exclude other heart diseases which 
correlated to fibrotic process, which was Ischemic 
Heart Disease (IHD). In classifying stage B and C 
heart failure, researchers examined whether there 
were any symptoms of heart failure before or at the 
moment of examination, prior heart failure 
symptoms are subjective.
Most of heart failure was treated with an 
ACEI, ARB, â-blockers, CCB, furosemide, 
spironolactone and thiazides could be a 
confounding factor, but it was still the therapeutic 
standard for heart failure patients.
CONCLUSION
There were no significant differences in the 
level of type I carboxy terminal propeptide 
procollagen (PIP) in the serum of heart failure 
groups of stage A, B and C. Researchers have not yet 
been able to give any suggestions for this study. 
Further research needs to be done by doing treadmill 
test and coronary angiography to exclude IHD and 
to classify stage B and C heart failure groups in a 
more objective way.
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